LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Inicio・Lista de Acciones・uniQure NV

uniQure NV

Cerrado

14.26 34.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.96

Máximo

15.02

Métricas clave
By Trading Economics
Ingresos	-43M -81M
Ventas	1.9M 5.6M
Margen de beneficio	-2,175.871
Empleados	209
EBITDA	432K -51M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+125.35% upside

Dividendos
By Dow Jones
Próximas Ganancias	8 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-870M 654M
Apertura anterior	-20.4
Cierre anterior	14.26

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

10.05 / 14.75 Soporte y Resistencia

uniQure NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 mar 2026, 13:13 UTC

Principales Movimientos del Mercado

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 ene 2026, 15:14 UTC

Principales Movimientos del Mercado

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov 2025, 13:34 UTC

Principales Movimientos del Mercado

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 sept 2025, 18:51 UTC

Ganancias

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

uniQure NV Esperado

Precio Objetivo

By TipRanks

125.35% repunte

Estimación a 12 meses

Media 24 USD 125.35%

Máximo 70 USD

Mínimo 9 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para uniQure NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para uniQure NV Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

10.05 / 14.75Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.